Gilead Files Truvada For HIV Pre-Exposure Prophylaxis
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has accepted Gilead Sciences' filing for the use of its HIV drug Truvada in pre-exposure prophylaxis (PrEP), a new indication that AIDS activists and others have been urging Gilead to seek in the EU for some time.